Contract analysis

I. Introduction and Purpose This memorandum was prepared in anticipation of our client Penterra Pharmaceuticals Corp.'s ("Penterra") motion for summary judgment, which is scheduled to be filed on February 11, 2022, in the above-captioned declaratory-judgment action against Vantage Medical Distribution, LLC ("Vantage"). The memorandum is intended to serve as the analytical foundation for the summary judgment brief and

II. Factual Background Relevant to Legal Analysis The following factual summary is drawn from the EDA, the documentary record produced in discovery, and the deposition testimony of three key witnesses. It is presented here to provide the context necessary for the legal analysis that follows. To the extent that factual disputes exist, they are noted; however, as discussed in the legal analysis, the material facts rele

Section 2.1 of the EDA grants Vantage "the exclusive right to distribute the Products within the Territory, as defined in Exhibit A." This exclusivity provision is the cornerstone of the commercial arrangement: within the Territory, Penterra agreed not to appoint any other distributor for the covered products, and Vantage agreed to certain minimum purchase commitments and marketing obligations. Exhibit A to the EDA d

Section 2.3 of the EDA further provides: "Distributor shall not actively solicit orders for, or deliver, the Products outside the Territory without Supplier's prior written consent." This provision expressly prohibits Vantage from distributing the Products outside the New England states absent Penterra's "prior written consent." The use of the phrase "prior written consent" is significant, as it imposes a written-con

Section 13.1 of the EDA (captioned "Amendments") states: "No amendment, modification, or waiver of any provision of this Agreement shall be effective unless set forth in a written instrument signed by both parties." The clause is expansive in scope: it covers amendments, modifications, and waivers. It requires that any such change be (i) set forth in a written instrument, and (ii) signed by both parties. The bilatera

Section 14.8 of the EDA (captioned "Entire Agreement") states: "This Agreement, including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." This is a standard integration or merger clause. Its effect is to establish the EDA as the complete and fin

III. Legal Analysis A. Enforceability of Written-Modification Clauses Under Massachusetts Law

1. The General Rule: Written-Modification Clauses Are Enforceable. Massachusetts courts consistently enforce contractual provisions requiring that amendments or modifications be in writing and signed by both parties. The law in this area is well-settled and has been applied by courts at all levels of the Massachusetts judiciary, including the Supreme Judicial Court ("SJC"), the Appeals Court, and the Superior Court's

2. Application to Section 13.1 of the EDA. Section 13.1 of the EDA requires that any amendment, modification, or waiver be "set forth in a written instrument signed by both parties." This language is clear and unambiguous. It imposes two conjunctive requirements: (i) the modification must be set forth in a written instrument, and (ii) the written instrument must be signed by both parties. Both requirements must be sa

3. Exceptions to the General Rule (and Why They Do Not Apply). Massachusetts law recognizes a limited number of narrow exceptions to the general rule that written-modification clauses are enforceable. We have analyzed each exception and conclude that none applies to the facts of this case. Waiver by Conduct. Some courts have held that a party may waive its right to enforce a written-modification clause through repeat

1. Integration Clauses Under Massachusetts Law. Massachusetts courts give effect to integration or merger clauses, which establish that the written agreement is the complete and final expression of the parties' agreement with respect to the subject matter thereof. An integration clause serves a critical function in commercial transactions: it ensures that the written agreement is the authoritative source of the parti

Section 14.8 of the EDA is a standard integration clause. It states that the Agreement, "including all Exhibits, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, representations, or agreements relating thereto, whether written or oral." The clause is broadly drafted and covers all "negotiations, representations, or agreements" — whet

2. The Parol Evidence Rule in Massachusetts. The parol evidence rule is a substantive rule of contract law that operates to exclude extrinsic evidence when a written contract is found to be the complete and final expression of the parties' agreement. Under Massachusetts law, when a contract is fully integrated, the parol evidence rule bars the introduction of extrinsic evidence — including prior or contemporaneous or

3. Interaction Between Integration Clause and Written-Modification Clause. The presence of both an integration clause (Section 14.8) and a written-modification clause (Section 13.1) in the EDA creates a dual barrier to Vantage's modification arguments. The integration clause establishes the four corners of the agreement — that is, it defines the universe of terms that constitute the parties' contractual rights and ob

1. The Doctrine of Course of Dealing. Course of dealing is a recognized concept in contract law, defined as a sequence of previous conduct between the parties to a particular transaction that establishes a common basis of understanding for interpreting their expressions and other conduct. The concept is codified in the Uniform Commercial Code, M.G.L. c. 106, § 1-303(b), which provides that "[a] 'course of dealing' is

2. Application to Vantage's Course-of-Dealing Argument. Vantage argues that Penterra's failure to object to Vantage's shipments of Oncalaris® to customers in the Tri-State Area, beginning in late 2019 (according to Vantage) or September 2020 (according to Penterra), and continuing through early 2021, established a course of dealing that effectively modified Exhibit A to include New York, New Jersey, and Pennsylvania

3. Distinguishing Course of Dealing from Waiver. Even if Penterra's delayed objection to Vantage's tri-state shipments could theoretically be characterized as a limited waiver of enforcement for a brief period, such a waiver would not constitute a permanent modification of the contract under Massachusetts law. The distinction between waiver and modification is well-established and legally significant. A waiver is a v

1. Elements of Promissory Estoppel Under Massachusetts Law. Promissory estoppel is an equitable doctrine that may, in appropriate circumstances, render a promise enforceable even in the absence of consideration or formal contractual requirements. Under Massachusetts law, the elements of promissory estoppel are: (1) a clear and definite promise; (2) the promisor reasonably expected that the promisee would rely on the

2. Application to the Facts. Vantage's promissory estoppel argument, which appears to be asserted as an alternative theory in its counterclaim, is based on the Kapoor Email and Penterra's alleged course of dealing. For the reasons set forth below, this argument fails to satisfy any of the four elements of the doctrine. Element 1: Clear and definite promise. The Kapoor Email states: "We're definitely open to exploring

IV. Analysis of Potential Counterarguments A. Vantage's Likely Arguments Based on the pleadings, discovery responses, and deposition testimony to date, we anticipate that Vantage will advance three principal counterarguments in opposition to Penterra's motion for summary judgment. We address each in turn.

1. The Kapoor Email as "Prior Written Consent" Under Section 2.3. Vantage may argue that Section 2.3 of the EDA — which prohibits Vantage from distributing Products outside the Territory "without Supplier's prior written consent" — establishes a different and lower threshold than Section 13.1's requirement for a "written instrument signed by both parties." Specifically, Vantage may contend that the Kapoor Email, even

2. Material Breach by Penterra (Meridian National Distributors). Vantage may argue that Penterra's execution of a term sheet with Meridian National Distributors, Inc. ("Meridian") on February 15, 2021 — under which Penterra would appoint Meridian as the exclusive distributor for Oncalaris® and Renuvesta® in New York, New Jersey, and Pennsylvania — constituted an anticipatory breach of the EDA and/or a breach of the i

3. Implied Covenant of Good Faith and Fair Dealing. Vantage's counterclaim alleges that Penterra breached the implied covenant of good faith and fair dealing by (a) failing to negotiate a territorial expansion in good faith after the Kapoor Email, (b) appointing Meridian as a distributor in the Tri-State Area, and (c) issuing the cease-and-desist letter in March 2021. Under Massachusetts law, every contract implies a